Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C28H44NO2.Cl.H2O |
| Molecular Weight | 480.123 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
O.[Cl-].CC1=CC(OCCOCC[N+](C)(C)CC2=CC=CC=C2)=CC=C1C(C)(C)CC(C)(C)C
InChI
InChIKey=XSTVKUYSCKWKCJ-UHFFFAOYSA-M
InChI=1S/C28H44NO2.ClH.H2O/c1-23-20-25(14-15-26(23)28(5,6)22-27(2,3)4)31-19-18-30-17-16-29(7,8)21-24-12-10-9-11-13-24;;/h9-15,20H,16-19,21-22H2,1-8H3;1H;1H2/q+1;;/p-1
| Molecular Formula | ClH |
| Molecular Weight | 36.461 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
| Molecular Formula | HO |
| Molecular Weight | 17.0073 |
| Charge | -1 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
| Molecular Formula | C28H44NO2 |
| Molecular Weight | 426.6545 |
| Charge | 1 |
| Count |
|
| Stereochemistry | RACEMIC |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
Approval Year
PubMed
| Title | Date | PubMed |
|---|---|---|
| Topical paromomycin/methylbenzethonium chloride plus parenteral meglumine antimonate as treatment of American cutaneous leishmaniasis: controlled study. | 1999 Aug |
|
| Randomized, controlled, double-blind trial of topical treatment of cutaneous leishmaniasis with paromomycin plus methylbenzethonium chloride ointment in Guatemala. | 2001 Nov |
|
| Leishmania major: in vitro and in vivo anti-leishmanial activity of paromomycin ointment (Leshcutan) combined with the immunomodulator Imiquimod. | 2007 Jun |
Patents
Sample Use Guides
1- Clean the affected area and completely cover with the ointment. A sterile dressing can be used to dress the area. 2- Apply the ointment twice a day, for about 10 days. If full recovery is not achieved, the doctor will consider administration of an additional 10-day course of treatment.
Route of Administration:
Topical
Methylbenzethonium chloride at 0.1 and 0.5 microg/ml inhibited the parasite development by 39.5% and 65.2%. Imiquimod (5-10 microg/ml) combined with either paromomycin (25, 50 and 100 microg/ml) or methylbenzethonium chloride (0.1 and 0.5 microg/ml) showed an anti-leishmanial additive effect.
| Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 15:38:31 GMT 2023
by
admin
on
Fri Dec 15 15:38:31 GMT 2023
|
| Record UNII |
890DE8DEBI
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
890DE8DEBI
Created by
admin on Fri Dec 15 15:38:31 GMT 2023 , Edited by admin on Fri Dec 15 15:38:31 GMT 2023
|
PRIMARY | |||
|
10139-80-7
Created by
admin on Fri Dec 15 15:38:31 GMT 2023 , Edited by admin on Fri Dec 15 15:38:31 GMT 2023
|
PRIMARY | |||
|
22760839
Created by
admin on Fri Dec 15 15:38:31 GMT 2023 , Edited by admin on Fri Dec 15 15:38:31 GMT 2023
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
PARENT -> SALT/SOLVATE | |||
|
ANHYDROUS->SOLVATE |
